Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence

Eli Lilly reported Q3 revenue of $24.4 billion, up 39% year over year, with Zepbound sales rising 49% to $5.4 billion and Mounjaro sales up 65% to $10.7 billion; the update sent shares up about 6%. The article highlights growth across newer non-GLP-1 medicines, including Kisunla, Jaypirca, Ebglyss and Omvoh, as well as label expansions and a broader pipeline. Remternetug may offer advantages over Kisunla, but it has not yet demonstrated superiority in Phase 3 studies.

Analysis

Diversification is an option, not yet a hedge. The four cited non-GLP-1 products together remain below 4% of quarterly revenue, versus roughly two-thirds from Mounjaro and Zepbound. Their growth rates look impressive off small bases; they do not yet insulate earnings if obesity-drug pricing, access, supply, or competition weakens. The label expansions improve addressable markets, but uptake, persistence, and net pricing—not approval headlines—will determine whether they become material contributors. Kisunla also carries meaningful execution uncertainty in a disease area where adoption and treatment logistics can constrain conversion of theoretical demand into sales.

Timing and competition: After the reported post-earnings price jump, near-term upside requires estimates to keep rising; the diversification narrative alone is unlikely to justify chasing. Over 1–3 months, monitor prescription trends, payer access and management’s full-year outlook. Over 6–18 months, successful scaling outside GLP-1s could reduce earnings concentration, while oral obesity therapies may broaden the market but also intensify competition and pressure injectable pricing—including for Lilly. Novo Nordisk is a relevant competitive read-through, not a clean hedge for Lilly-specific execution.

Contrarian view: The article treats pipeline breadth as evidence of durable diversification, but revenue mix says the exposure remains concentrated. No valuation or forward-estimate data are provided, so the earnings beat and positive narrative do not establish attractive entry value. The thesis weakens if GLP-1 growth/access deteriorates before newer products scale, or if non-GLP launches fail to sustain uptake; it strengthens with repeated estimate increases and demonstrable revenue contribution beyond GLP-1s.

Key Decisions for Investors

• Avoid chasing the post-earnings gap solely on the diversification thesis. For new exposure, wait for valuation and consensus-revision data; consider adding only if estimates rise without a material deterioration in access or pricing.
• Track quarterly non-GLP-1 revenue contribution, launch persistence and net pricing—not year-over-year growth rates alone. Reassess if these products remain immaterial while GLP-1 growth decelerates.
• Set a 1–3 month alert for prescription/access trends and any guidance revision; over 6–18 months, monitor whether expanded labels translate into sustained adoption. A downward outlook revision or deteriorating access would falsify the near-term bullish setup.
• Treat remternetug as pipeline optionality, not current earnings support, until later-stage evidence establishes efficacy, safety and a practical advantage over existing treatment.